NCT01998035 2024-08-22Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid MalignanciesColumbia UniversityPhase 1/2 Terminated58 enrolled 11 charts
NCT05105412 2024-07-08Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell LymphomasNational Health Research Institutes, TaiwanPhase 1/2 Terminated12 enrolled
NCT02440685 2023-06-07A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid TumorsAsana BioSciencesPhase 1/2 Terminated51 enrolled 18 charts
NCT04444141 2022-10-19A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell LymphomaAkesoPhase 1/2 Terminated6 enrolled
NCT02535247 2022-07-08Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin LymphomaFox Chase Cancer CenterPhase 1/2 Terminated17 enrolled 7 charts
NCT01805037 2021-09-01Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasNorthwestern UniversityPhase 1/2 Terminated20 enrolled 17 charts